archaeosome-OVA

Archaeosome-OVA is a vaccine formulation in which **ovalbumin (OVA), a model protein antigen**, is encapsulated within archaeosomes—liposomes composed of unique ether lipids extracted from archaeal microorganisms such as Methanobrevibacter smithii, Halobacterium salinarum, or Thermoplasma acidophilum[1][2][4][5][7][8]. Archaeosome-OVA acts as a self-adjuvanting delivery vehicle designed to enhance both **CD8⁺ cytotoxic T cell and antibody responses** against the entrapped antigen. It has been studied primarily in preclinical cancer immunotherapy models, such as murine B16-OVA melanoma, where it stimulates robust antigen-specific immune responses, providing prophylactic and therapeutic protection by promoting CD8⁺ T cell-mediated tumor immunity[2][5][8]. The activity of archaeosome-OVA is further enhanced when combined with checkpoint inhibitors (e.g., anti-PD-1, anti-PD-L1, anti-CTLA-4), resulting in synergistic antitumor effects[2]. The mechanism involves efficient antigen presentation via MHC class I to CD8⁺ T cells, immune potentiation, and innate immunostimulation due to intrinsic adjuvant properties of archaeal lipids. Archaeosome formulations can be tailored for immune profile via lipid composition[1][7][9].

Other names

archaeosome-OVAOVA-archaeosomesarchaeosome-entrapped OVA